Blog

  • THERABODY’S THERAFACE DEPUFFING WAND AND THERMBACK LED RECOGNIZED ON TIME’S BEST INVENTIONS OF 2025

    THERABODY’S THERAFACE DEPUFFING WAND AND THERMBACK LED RECOGNIZED ON TIME’S BEST INVENTIONS OF 2025

    Dual Recognition Underscores Therabody’s Leadership in Driving the Future of Wellness with Science-Backed, Clinically Proven Innovations

    LOS ANGELES, Oct. 9, 2025 /PRNewswire/ — Therabody, the global leader in wellness…

    Continue Reading

  • How firms respond to import competition: Labour force reduction, product/industry switching, and off-shoring

    As global trade has expanded – especially with the ascent of China – concerns about job losses and deindustrialisation in high-income countries have grown. While many studies document the level of impact of import competition on employment, we know less about how firms adapt. Do they downsize, switch product lines/industries, or reorganise production through offshoring to cushion the blow? In a recet paper (Ito and Matsuura 2025), we address these questions using a uniquely rich panel of Japanese firms spanning 1997–2014, focusing on three margins of adjustment: employment (especially production workers), industry switching, and offshoring (imports of intermediates from Asia). We also ask when these adjustments occur – either immediately or with a lag.

    Figure 1 documents a clear rise in Chinese import penetration into Japan from the late 1990s onward, with only a crisis-era pause. Over the same period, Japan’s manufacturing share of employment fell from 20.8% in 1995 to 15.3% in 2015) (Figure 2), providing prima facie evidence of structural pressure.

    Figure 1 Import penetration ratio from China

    Note: Chinese import penetration is computed as Import from China/Domestic demand, where Domestic demand = Domestic production + Imports from the world – Exports to the word.
    Source: Authors’ calculations based on System of National Accounts (Cabinet Office) and JIP database (RIETI).

    Figure 2 Share of manufacturing employment in Japan

    Source: Authors’ computation from the System of National Accounts (Cabinet Office of Japan).

    How do firms respond to intensifying import competition from China? Table 1 presents the distribution of firms according to their response patterns. Firms are categorised into four groups based on their reactions. The first group consists of firms that neither reduce employment nor switch industries, labeled “NoAdjust”. The second group includes firms that adjust employment only (“EmplAdjustOnly”), while the third group comprises firms that switch industries only (“IndSwitchOnly”). The fourth group consists of firms that adopt both strategies – employment adjustment and industry switching – labeled “BothEmplSwitch”. Employment adjustment is defined as a reduction of 10% or more in the number of production workers over the previous five years. Industry switching refers to a change in a firm’s primary four-digit industry classification.

    To assess the impact of Chinese import competition, we compare firms operating in the top and bottom five industries based on the extent of change in Chinese import penetration. Among all firms shown in column (1), 54% made no adjustments (NoAdjust), 30.5% implemented only employment reductions (EmplAdjustOnly), 9.2% switched industries without adjusting employment (IndSwitchOnly), and 6.3% pursued both strategies (BothEmplSwitch). Columns (2) and (3) present firms in the bottom five and top five industries, respectively, based on the degree of change in Chinese import penetration. In the bottom five industries, shown in column (2), 58% of firms did not implement any adjustments (NoAdjust). While the share of firms engaging in industry switching – either alone or in combination with employment reductions – was low, the proportion of firms implementing only employment adjustments was similar to that observed for all firms. By contrast, in the top five industries, presented in column (3), the share of firms that made no adjustments was lower, at 48%. The proportion of firms that engaged only in industry switching or that strategy in combination with employment reduction was notably higher at 11% and 9.7%, respectively. These patterns suggest that firms exposed to greater import competition from China are more likely to respond with a combination of employment adjustment and industry switching.

    Table 1 Firm’s reaction patterns

    Source: Authors’ computation from the Basic Survey of Japanese Business Structure and Activities (BSJBSA)and the Census of Manufacture (COM) data of the Ministry of Economy, Trade and Industry (METI).

     Econometric analyses using the multinomial logit model demonstrated the following:

    • Rising imports have led many firms to reduce their workforce, with production workers experiencing significant losses, in line with the cases shown for the US in Autor et al. (2013) and Acemoglu et al. (2016).
    • Firms that engaged in product switching experienced less severe employment losses than those that did not, suggesting that product switching could be an effective coping strategy. This finding resonates with those found in Iacovone et al. (2013) and Miranda et al. (2011), among others.
    • Import competition has an immediate effect on the employment of production workers, whereas overall firm-level employment adjustment and product switching tend to occur with a delay of two to three years.
    • Offshoring also plays a crucial role in mitigating the adverse effects of import competition. This finding, which complements that in Hayakawa et al. (2021), highlights the importance of offshoring in sustaining employment and suggests that globalisation should not simply be regarded as a factor that reduces job opportunities.

    Author’s note: The main research on which this column is based (Ito and Matsuura 2025) first appeared as a Discussion Paper of the Research Institute of Economy, Trade and Industry (RIETI) of Japan.

    References

    Acemoglu, D, D Autor, D Dorn, G Hanson and B Price (2016), “Import Competition and the Great US Employment Sag of the 2000s”, Journal of Labor Economics 34(1): S142-S198.

    Autor, D, D Dorn and G Hanson (2013), “The China Syndrome: Local Labor Market Effect of Import Competition in the United States”, American Economic Review 103(6): 2121-2168.

    Hayakawa, K, T Ito and S Urata (2021), “Impacts of Increased Chinese Imports on Japan’s Labor Market”, Japan and the World Economy 59, 101087.

    Ito, T and T Matsuura (2025), “Import Competition and Restructuring Strategies: Evidence from Japanese firm-level data”, RIETI Discussion Paper Series 25-E-059

    Iacovone, L, F Rauch and L A Winters (2013), “Trade as an engine of creative destruction: Mexican experience with Chinese competition”, Journal of International Economics 89(2): 379–392.

    Miranda, V, M-M Badia and I Van Beveren (2012), “Globalization drives strategic product switching,” Review of World Economics 148: 45-72.

    Continue Reading

  • Integrating pollution registers for corporate climate-risk assessment

    The year 2024 was confirmed by the Copernicus Climate Change Service to be the warmest year on record globally, and the first calendar year that the average global temperature exceeded 1.5°C above its pre-industrial level. As climate change intensifies, the financial and regulatory risks facing businesses are under increasing scrutiny. Governments and financial institutions worldwide are aligning corporate reporting requirements with the recommendations of the Task Force on Climate-related Financial Disclosures.

    The EU has taken a decisive step by implementing the Corporate Sustainability Reporting Directive (European Commission 2023), mandating around 50,000 companies, including 10,000 foreign companies, to report on climate-related risks from 2025. While disclosure requirements are becoming more stringent, recent studies suggest that corporate climate disclosure is becoming too costly and often a mere box-ticking exercise, with firms engaging in ‘greenwashing’ or selective reporting of non-material risks (Bingler et al. 2022). This raises a crucial question: how can investors, regulators, and consumers ensure they have a clear, standardised, and comparable understanding of climate risks across industries and geographies at a reasonable cost?

    In November 2024, European Commission President Ursula von der Leyen announced the Omnibus Environmental, Social, and Governance (ESG) Regulation to consolidate and simplify corporate sustainability reporting obligations. Our background research and this column recommend a methodology that can support the simplification of reporting, while providing comparable and standardised data and maintaining reporting requirements for a large number of companies without extra burden.

    A novel and cost-effective approach to measuring climate risk

    In our recent research (Erhart et al. 2025), we propose a comprehensive method for assessing corporate climate risks by integrating data from major pollutant release and transfer registers and greenhouse-gas reporting programmes with satellite observations across 30 countries, including Australia, Canada, the EU, and the US. Our study analyses data from 70,000 industrial firms and their 170,000 facilities, offering an unprecedented large-scale approach to evaluating both transition and physical climate risks required by the Corporate Sustainability Reporting Directive and the related European Sustainability Reporting Standard (Figure 1).

    Figure 1 Climate change transition and physical risks covered in our study

    Notes: ESRS: European Sustainability Reporting Standard. GHG: greenhouse gas.
    Data sources: European Environment Agency, EU Pollutant Release and Transfer Register, US Environmental Protection Agency (EPA), EPA Toxic Release Inventory, Facility Level Information from the EPA Greenhouse Gases Tool (FLIGHT), Canadian National Pollutant Inventory, Australian Clean Energy Regulator, National Greenhouse and Energy Reporting, Canadian Greenhouse Gas Reporting Programme, Australian National Pollutant Release Inventory.

    Key findings: Climate risks are not uniform

    Our research highlights that climate risks manifest differently across industries and locations.

    1. Transition risk. Measured through reported greenhouse gas emissions, transition risk is highest for industrial plants in the US. Companies with high emissions may continue to face regulatory and market pressures to decarbonise or risk losing investor confidence in the long run.

    2. Physical risk. Assessed via historical data on cooling energy needs (heat risk), flood exposure, and photovoltaic power potential, physical risks are highly location-dependent. For instance, heat risk is more severe for firms in Australia, Southern Europe, and the southern US, while flood exposure is more pronounced in Central Europe and the eastern US (Figures 2 and 3).

    Figure 2 Flood exposure (maximum historical water discharge at industrial company sites)

    Notes: White bubbles on the map indicate company facilities without historical flood risk, while blue bubbles indicate company facility locations with historical flood risk.
    Source: Erhart et al. (2025).

    Figure 3 Heat risk of industrial company sites in the sample in cooling degree days

    Note: Map colour scale: green is the lowest heat risk (in terms of cooling degree days) and red is the highest. 2019 observations were used.
    Source: Erhart et al. (2025).

    3. No strong correlation between transition and physical risks. Unlike common assumptions, our findings indicate that transition and physical risks are not necessarily correlated at the company level. Some firms may have low emissions but face high physical risks due to extreme weather exposure, while others with high emissions may operate in less climate-vulnerable locations.

    Figure 4 No strong correlation between transition and physical risks

    Notes: Combined figure of Pearson correlation ratios and significance levels (upper right cells), indicator histograms (diagonal cells), pairwise scatter plots of indicators (lower left cells). (a) Heat risk (cooling degree days, cdd). (b) Flood risk, maximum historical water discharge (metres). (c) Photovoltaic potential, long-term average daily total of kilowatt-hour (kWh) from optimally tilted 1kWp panel. (d) greenhouse gas (equivalent in kilogrammes, Co2eqKg). 2019 observations were used for the greenhouse gas emissions.
    Source: Erhart et al. (2025).

    Policy and investment implications

    These findings have critical implications for policymakers, investors, and corporate managers.

    • Standardising risk disclosure. The lack of correlation between transition and physical risks underscores the need for a more comprehensive risk-assessment framework that captures both dimensions. Current reporting standards should evolve to reflect this complexity.
    • Investor strategy and portfolio diversification. Investors need to look beyond headline emissions figures and assess the physical climate risks embedded in their portfolios. Firms with high flood or heat exposure may require additional adaptation investments.
    • Corporate risk management. Businesses must develop holistic climate-risk strategies that integrate both mitigation (reducing emissions) and adaptation (enhancing resilience to climate impacts).

    A call for better data integration

    Our study demonstrates that publicly available pollution registers and satellite observations of physical climate risks offer a valuable, yet underutilised, resource for regular climate-risk assessments. However, these datasets remain fragmented across jurisdictions, limiting their effectiveness for global risk evaluation. We recommend greater international coordination in environmental reporting and data integration to enhance transparency and comparability.

    With upcoming regulatory changes, companies, investors, and regulators must adopt more rigorous and data-driven approaches to climate-risk assessment. By leveraging pollution registers and satellite imaging and radar observations, we can gain a clearer and more actionable picture of industrial climate risks, ultimately fostering a more resilient and sustainable global economy.

    References

    Bingler, J A, M Kraus, M Leippold and N Webersinke (2022), “Cheap talk and cherry-picking: What ClimateBert has to say on corporate climate risk disclosures”, Finance Research Letters 47(Part B).

    Copernicus Climate Change Service (2025), Copernicus: 2024 is the first year to exceed 1.5°C above pre-industrial level, Global Climate Highlights 2024.

    Erhart, S, S Szabó, and K Erhart (2025), “Integrating pollutant registers for the climate change risk evaluation of industrial companies in Australia, Europe and North America”, Nature Scientific Reports 15(1207).

    European Commission (2023), “New rules on corporate sustainability reporting: The Corporate Sustainability Reporting Directive”.

    EU (2023), “Regulation of the European Parliament and of the Council of 27 November 2019 on sustainability-related disclosures in the financial services sector”, PE/87/2019/REV/1.

    Continue Reading

  • The Woman in Cabin 10 film review — Keira Knightley stars in a story desperately seeking intrigue

    The Woman in Cabin 10 film review — Keira Knightley stars in a story desperately seeking intrigue

    Stay informed with free updates

    Based on a novel by Ruth Ware, queen of lifestyle whodunits, The Woman in Cabin 10 could have been called The Strange Case of the Missing…

    Continue Reading

  • Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)

    Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)

    • EYDENZELT® is approved for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR)
    • Celltrion plans to enter the U.S. ophthalmology market to meet diverse needs of patients suffering from various eye conditions

    INCHEON, South Korea, Oct. 9, 2025 /PRNewswire/ — Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept), for the treatment of neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME) and diabetic retinopathy (DR).[1]

    Aflibercept is a VEGF inhibitor formulated as an injection for the eye that blocks the growth of new blood vessels and decreases the ability of fluid to pass through blood vessels (vascular permeability) in the eye by blocking VEGF-A and placental growth factor (PlGF), two growth factors involved in ocular angiogenesis.

    “Timely access to effective therapies is essential for individuals affected by retinal diseases. We are proud to have EYDENZELT approved by the FDA, and we look forward to expanding the availability and access of biological treatments across the U.S.,” said Dr. Juby Jacob-Nara, Senior Vice President and Chief Medical Officer at Celltrion USA. “With EYDENZELT demonstrating biosimilarity to its reference product, we believe this approval will mark a significant milestone in the treatment landscape of retinal diseases—helping physicians broaden their options and improving patient outcomes.”

    The FDA approval was based on a totality of evidence including analytical, nonclinical, and clinical data. In a randomized, double-masked, parallel-group, multicenter phase III study of EYDENZELT, the efficacy, safety, pharmacokinetics, and immunogenicity of EYDENZELT was compared to EYLEA in patients with diabetic macular edema (DME). The 52-week trial included 348 patients with DME. The primary endpoint was the change in best corrected visual acuity measured at week 8 from baseline, comparing EYDENZELT and EYLEA. Results of the study showed that EYDENZELT met the predefined equivalence criteria, and secondary endpoints of efficacy, safety, and immunogenicity also showed trends similar to EYLEA.

    “Advanced age-related macular degeneration (AMD) is a leading cause of irreversible blindness and visual impairment in the world and nearly 20 million people in the U.S. are living with some form of age-related macular degeneration,” said Dr. David M. Brown, Director, Retina Consultants of Texas Research Centers, Co-chair, Medical Leadership Board Retina Consultants of America. “EYDENZELT will be an important new addition to our options for the treatment of our patients with serious retinal diseases.”

    EYDENZELT is Celltrion’s first FDA-approved biologic product in ophthalmology. EYDENZELT was also approved by the European Commission (EC) in February 2025.   

    ###

    About EYDENZELT® ( aflibercept-boav ) 

    EYDENZELT® (aflibercept-boav) is a vascular endothelial growth factor (VEGF) inhibitor referencing EYLEA® (aflibercept). EYDENZELT is approved based on a comprehensive data confirming the therapeutic equivalence EYLEA. In the U.S., EYDENZELT is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME) and diabetic retinopathy (DR).

    INDICATIONS

    EYDENZELT® (aflibercept-boav) is indicated for the treatment of patients with:

    • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
    • Macular Edema Following Retinal Vein Occlusion (RVO)
    • Diabetic Macular Edema (DME)
    • Diabetic Retinopathy (DR)

    IMPORTANT SAFETY INFORMATION

    • EYDENZELT is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, and hypersensitivity to aflibercept or any of the excipients in EYDENZELT.
    • Instruct patients and/or caregivers to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately.
    • Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
    • There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including aflibercept products. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).
    • The most common adverse reactions (≥5%) reported in patients receiving aflibercept were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.

    For more information, see Full Prescribing Information .

    About Celltrion , Inc.

    Celltrion, Inc. is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people’s lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world’s first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us and stay updated with our latest news and events on our social media: LinkedIn, Instagram, X, and Facebook.

    About Celltrion USA

    Celltrion USA is Celltrion’s U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion currently has ten biosimilar products approved by the U.S. FDA: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), AVTOZMA® (tocilizumab-anho), STEQEYMA® (Ustekinumab-stba) STOBOCLO® (denosumab-bmwo), OSENVELT® (denosumab-bmwo), and OMLYCLO® (omalizumab-igec) as well as a novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion’s unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit www.celltrionusa.com, and stay updated with our latest news and events on our social media: LinkedIn.

    FORWARD-LOOKING STATEMENT

    Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion, Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws.

    These statements may be also identified by words such as “prepares”, “hopes to”, “upcoming”, “plans to”, “aims to”, “to be launched”, “is preparing”, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.

    In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion, Inc. and its subsidiaries’ management, of which many are beyond its control.

    Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect to the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

    Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company’s business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements.

    Celltrion, Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

    Trademarks

    EYDENZELT® is a registered trademark of Celltrion, Inc.
    EYLEA® is a registered trademark of Regeneron Pharmaceuticals Inc.

    References

    [1] EYDENZELT U.S. prescribing information (2025)

    US–24-00028

    For further information please contact:
    Katie Gallagher
    [email protected]
    +1 617-657-1324

    SOURCE Celltrion


    Continue Reading

  • Laura Agricola-Moss joins SICKDOGWOLFMAN in the role of Strategy Director – Campaign Brief

    Laura Agricola-Moss joins SICKDOGWOLFMAN in the role of Strategy Director – Campaign Brief

    | | No Comments

    Melbourne independent,…

    Continue Reading

  • Zero emission zones: The Netherlands’ path to cleaner urban freight

    Zero emission zones: The Netherlands’ path to cleaner urban freight

    A framework for success

    The Netherlands’ ZEZ-Fs evolved from voluntary collaboration between local authorities and the private sector to test zero-emission urban freight solutions in regional pilots. By 2019, key targets from these collaborations were embedded in national legislation that committed 30–40 larger municipalities to establish ZEZ-Fs by 2025. Subsequent legislation established that zones must be announced at least 4 years in advance, helping to ensure that freight operators have sufficient time to prepare.

    Alongside the flexibilities described above, the national government and local authorities have introduced a range of measures to prepare local publics for the ZEZ-F rollout. These include:

    Subsidies, like the national Subsidy Scheme for Emission-Free Commercial Vehicles, which offered up to €5,000 per battery electric van between 2021 to 2024, and the Purchase Subsidy for Zero-Emission Trucks, which offers up to €115,200 for buying or leasing N2 or N3 trucks.

    Tax incentives that exempt zero-emission vans from the one-time registration tax of €74.41 per gram CO2/km introduced in 2025, when the previous registration tax exemption for all new commercial vans was removed.

    Support for charging infrastructure deployment, such as the Public Charging Infrastructure Heavy Transport Subsidy Scheme, which offers a subsidy of at least €25,000 for the deployment of public fast charging infrastructure.

    Category B licenses for heavy zero-emission vans: A category B license allows the operation of vehicles with a gross vehicle weight of up to 3.5 tonnes. To account for the added weight of BEVs, an EU exemption allows drivers with a standard B license to operate zero-emission vans up to 4.25 tonnes. This exemption was introduced as part of a pilot program in the Netherlands and was originally set to expire in 2024, but has been extended pending a new EU driving license directive.

    While not exhaustive, these measures have contributed to the adoption of zero-emission vans and trucks and to the broader framework supporting the ZEZ-Fs rollout.

     

    Lessons for other countries

    The Dutch experience offers insights for other governments considering ZEZ-Fs.

    Starting with voluntary collaboration allows governments to build trust and test solutions before regulation. Real-world pilots enabled scalable testing before regulations kicked in, building trust and minimizing disruption while seeding the legal frameworks and stakeholder commitment that made implementation successful.

    Providing adequate lead times and financial support to ease transitions is critical. Adequate lead times, alongside purchase subsidies, technical guidance, and support for infrastructure rollout, have helped accelerate the Netherlands’ fleet transition. Early investment in one of Europe’s densest charging infrastructure networks, plus financial support, gave businesses the confidence and means to shift.

    Combining national rules with local flexibility can help meet diverse urban needs. By allowing cities to tailor ZEZ boundaries and complementary measures within a consistent national framework, the Netherlands has avoided policy fragmentation while also respecting cities’ diverse logistical needs. This approach also benefits businesses operating across multiple cities by providing clear, uniform regulations that enable straightforward, long-term planning. In turn, this predictability helps manufacturers and suppliers to better align their production and development efforts to meet the growing demand for BEVs.

    Prioritizing gradual implementation with clear, fixed deadlines can help balance policy ambition with business realities. The transitional periods for different vehicle categories in the Netherlands has balanced environmental objectives with practical business realities, providing adjustment time while advancing toward zero-emission requirements.

    The Netherlands shows how strong policy frameworks—combining clear regulations with support measures—can accelerate the shift to zero-emission commercial vehicles. Its collaborative, bottom-up approach has laid the foundation for broader urban logistics transformation. As cities pursue climate and air quality goals, the Dutch model offers a proven path to scale zero-emission freight while easing the transition for businesses.

    Continue Reading

  • Vodafone gives the world’s most questionably-existent creatures a rude shock in new iPhone 17 Pro launch campaign via Thinkerbell – Campaign Brief

    Vodafone gives the world’s most questionably-existent creatures a rude shock in new iPhone 17 Pro launch campaign via Thinkerbell – Campaign Brief

    | | No Comments

    In telco-land, the release of the new iPhone is kind of...


    Continue Reading

  • Solfrid Koanda crowned 86kg champion in front of King Harald V

    Solfrid Koanda crowned 86kg champion in front of King Harald V

    Norway’s Solfrid Koanda solidified her status as a national hero on Thursday (9 October), lifting a total of 272kg to claim the women’s 86kg world title at the 2025 IWF World Weightlifting Championships in Førde, Norway.

    She did so in front of…

    Continue Reading

  • Final Fantasy 7, 8, and 9 Physical Editions for Switch Are Up for Preorder

    Final Fantasy 7, 8, and 9 Physical Editions for Switch Are Up for Preorder

    The latest versions of the PS1-era Final Fantasy games are getting physical editions for Nintendo Switch on December 9. Final Fantasy VII and Final Fantasy VIII Remastered are being released together in a “twin-pack” box, while Final Fantasy…

    Continue Reading